Metrifonate. Treatment of Alzheimer's disease, acetylcholinesterase inhibitor

Drugs of the Future

Volumn 23, Issue 5, 1998, Pages 491-497

  Mucke, Hermann A M ^a  

^a Sanochemia Pharmazeutika AG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DICHLORVOS; GALANTAMINE; METRIFONATE; NEGUVON; PHYSOSTIGMINE; SYNAPTON; TACRINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; CEREBELLUM HYPOPLASIA; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEG CRAMP; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; RAT; REVIEW; RHINITIS; TREMOR;

EID: 0031818646     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.05.457485     Document Type: Review

References (58)

1. Barthel, W.F., Giang, P.A., Hall, S.A. Dialkyl alpha-hydroxyphosphonates derived from chloral. J Amer Chem Soc 1954, 76: 4186-7.
2. Lebrun, A., Cerf, C. Bull Med Health Org 1960, 22: 579-82.
3. Snellen, W.M. Therapeutic properties of metrifonate. Acta Pharmacol Toxicol 1981, 49: 114-7.
4. Becker, R.E., Giacobini, E. Pharmacokinetics and pharmacodynamics of acetylcholinesterase inhibition - Can acetylcholine levels in brain be improved by Alzheimer's disease? Drug Dev Res 1988, 14: 235-46.
5. Becker, R.E., Giacobini, E. (Board Trustees Southern Illinois Univ.). Method of medical treatment of Alzheimer's disease. US 4950658.
6. Lange, C. The identification of a metabolite of trichlorfon. Z Chem 1980, 20: 446-7.
7. Modak, A.T., Stavinoha, W.B., Weintraub, ST. Dichlorvos and the cholinergic system: Effects on cholinesterase and acetylcholine and choline contents of rat tissues. Arch Int Pharmacodyn Ther 1975, 217: 293-301.
8. Stavinoha, W.B., Modak, A.T., Weintraub, S.T. Rate of accumulation of acetylcholine in discrete regions of the rat brain after dichlorvos treatment. J Neurochem 1976, 27: 1375-8.
9. Nordgren, I., Bergstrom, M., Holmstedt, B., Sandoz, M. Transformation and action of metrifonate. Arch Toxicol 1978, 41: 31-41.
10. Ogane, N., Giacobini, E., Messamore, E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res 1992, 17: 489-95.
11. Soininen, H., Unni, L., Shillcutt, S. Effect of acute and chronic cholinesterase inhibition on biogenic amines in rat brain. Neurochem Res 1990, 15: 1185-90.
12. Nordgren, I., Karlen, B., Kimland, M. Metrifonate and tacrine: A comparative study on their effect on acetylcholine dynamics in mouse brain. Pharmacol Toxicol 1992, 71: 236-40.
13. Mori, F., Cuadra, G., Giacobini, E. Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 1995, 20: 1081-8.
14. Hinz, V.C., Blokland, A., van der Staay, F.J., Gebert, I., Schuurman, T., Schmidt, B.H. Receptor interaction profile and CNS general pharmacology of metrifonate and its transformation product dichlorvos in rodents. Drug Dev Res 1996, 38: 31-42.
15. Hinz, V.C., Grewig, S., Schmidt, B.H. Metrifonate and dichlorvos: Effects of a single oral administration on cholinesterase activity in rat brain and blood. Neurochem Res 1996, 21: 339-45.
16. Pacheco, G., Palacios-Esquivel, R., Moss, D.E. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: Selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther 1995, 274: 767-70.
17. Bassant, M.H., Jazat-Poindessous, F., Lamour, Y. Effects of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cerebr Blood Flow Metab 1996, 16: 1014-25.
18. Björklund, M., Jäkala, P., Schmidt, B., Riekkinen, M., Koivisto, E., Riekkinen, P. An indirect cholinesterase inhibitor, metrifonate, increases neocortical EEG arousal in rats. Neuroreport 1996, 7: 1097-101.
19. Kronforst-Collins, M.A., Moriearty, P.L., Ralph, M. et al. Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits. Pharmacol Biochem Behav 1997, 56: 103-10.
20. Riekkmen, R.J., Schmidt, B., Stefanski, R., Kuitunen, J., Riekkinen, M. Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats. Eur J Pharmacol 1996, 309: 121-30.
21. Riekkinen, P.J., Schmidt, B., Riekkinen, M. Behavioral characterization of metrifonate-improved acquisition of spatial information in medial septum-lesioned rats. Eur J Pharmacol 1997, 323: 11-9.
22. Riekkinen, M., Schmidt, B.H., Riekkinen, P.J. Subchronic treatment increases the duration of the cognitive enhancement induced by metrifonate. Eur J Pharmacol 1997, 338: 105-10.
23. Itoh, A., Nitta, A., Hirose, M., Hasegawa, T., Nabeshima, T. Effects of metrifonate on impairment of learning and dysfunction of cholinergic neuronal system in basal forebrain-lesioned rats. Behav Brain Res 1997, 83: 165-7.
24. Scali, C., Giovannini, M.G., Bartolini, L. et al. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol 1997, 325: 173-80.
25. Dachir, S., Schmidt, B., Levy, A. Effects of metrifonate on radial arm maze acquisition in middle-aged rats. Brain Res 1997, 777: 251-4.
26. van der Staay, F.J., Hinz, V.C., Schmidt, B.H. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J Pharmacol Exp Ther 1996, 278: 697-708.
27. Jakala, P., Riekkinen, M., Bjorklund, M., Koivisto, E., Schmidt, B., Riekkinen, P.J. Effects of combined nimodipine and metrifonate on rat cognition and cortical EEG. Eur J Pharmacol 1996, 318: 239-50.
28. Riekkinen, M., Schmidt, B., Kuitunen, J., Riekkinen, P.J. Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior. Eur J Pharmacol 1997, 322: 1-9.
29. Riekkinen, P.J., Schmidt, B., Jakala, P., Koivisto, E., Bjorklund. M. Chronic nimodipine and acute metrifonate treatment decreases age-related cortical high voltage spindles in rats. Psychopharmacology 1997, 129: 91-5.
30. Hinz, V.C., Grewig, S., Schmidt, B.H. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996, 21: 331-7.
31. Hallak, M., Giacobini, E. A comparison of the effects of two inhibitors of brain cholinesterase. Neuropharmacology 1987, 26: 521-30.
32. Hallak, M., Giacobini, E. Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989, 28: 199-206.
33. Nordgren, I., Bengtsson, E., Holmstedt, B., Pettersson, B.M. Levels of metrifonate and dichlorovos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil. Acta Pharmacol Toxicol 1981, 49(Suppl. 5): 79-86.
34. Aden-Abdi, Y., Villen, T., Ericsson, O., Gustafsson, L.L., Dahl-Puustinen, M.L. Metrifonate in healthy volunteers: Interrelationship between pharmacokinetic properties, cholinesterase inhibition and side effects. Bull World Health Organ 1990, 68: 731-6.
35. Abdi, Y.A., Villen, T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 1991, 68: 137-9.
36. Nordgren, I. Quantitation of metrifonate and dichlorvos in blood and tissues by gas chromatography-mass spectrometry. Fundam Appl Toxicol 1981, 1: 230-7.
37. Villen, T., Abdi, Y.A., Ericsson, O., Gustafsson, L.L., Sjoqvist. F. Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry. J Chromatogr 1990, 529: 309-17.
38. Unni, L.K., Hannant, M.E., Becker, R.E. High-performance liquid chromatographic method using ultraviolet detection for measuring metrifonate and dichlorvos levels in human plasma [see comments]. J Chromatogr 1992, 573: 99-103.
39. Unni, L.K., Womack, C., Hannant, M.E., Becker, R.E. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Meth Find Exp Clin Pharmacol 1994, 16: 285-9.
40. Nordgren, I., Holmstedt, B., Bengtsson, E., Finkel, Y. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with Bilarcil. Amer J Trop Med Hyg 1980, 29: 426-30.
41. Moriearty, P.L., Thornton, S.L., Becker, R.E. Transdermal patch delivery of acetylcholinesterase inhibitors. Meth Find Exp Clin Pharmacol 1993, 15: 407-12.
42. Boberg, M., Kanhai, W., Kern, A., Muschalek, V., Pleiss, U. (Bayer AG). Drug containing (-)-metriphonate. EP 669826, JP 95507280, US 5629300, WO 9324130.
43. Gaines, T.B. Acute toxicity of pesticides. Toxicol Appl Pharmacol 1969, 14: 515-34.
44. Batzinger, R.P., Bueding, E. Mutagenic activities in vitro and in vivo of five antischistosomal compounds. J Pharmacol Exp Ther 1977, 200: 1-9.
45. 7-alkylation in mice in vivo by metrifonate - Discussion of possible genotoxic risk in mammals. Acta Pharmacol Toxicol 1981, 49(Suppl. 5): 40-50.
46. Badawi, A.F., Awney, H.A., Mostafa, M.H. Formation of promutagenic methylation damage in tissue-DNA of mice treated with antischistosomal agents. Cancer Lett 1993, 75: 167-73.
47. Moutschen-Dahmen, J., Moutschen-Dahmen, M., Degraeve, N. Metrifonate and dichlorvos: Cytogenetic investigations. Acta Pharmacol Toxicol 1981, 49(Suppl. 5): 29-39.
48. Madrigal-Bujaidar, E., Cadena, S.R., Trujillo-Valdes, V.M., Cassani, M. Sister-chromatid exchange frequencies induced by metrifonate in mammalian in vivo and in vitro systems [see comments]. Mutat Res 1993, 300: 135-40.
49. Belchev, L., Khristov, T., Chifudov, D. Metrifonate-induced congenital tremors in piglets. Vet Med Nauki 1981, 18: 77-82.
50. Machemer, L. Chronic toxicity of metrifonate. Acta Pharmacol Toxicol 1981, 49(Suppl. 5): 15-28.
51. Mostafa, M.H., Swelem, S.M., Farag, H.F. Modification of cytochrome P-450, NADPH-cytochrome c reductase and aryl hydrocarbon hydroxylase activities by schistosomicidal drugs. Biochem Pharmacol 1989, 38: 251-5.
52. Moriearty, P.L., Womack, C.L., Dick, B.W., Colliver, J.A., Robbs, R.S., Becker, R.E. Stability of peripheral hematological parameters after chronic acetylcholinesterase inhibition in man. Amer J Hematol 1991, 37: 280-2.
53. Becker, R.E., Colliver, J.A., Elble, R. et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer disease: Report of an open trial Drug Dev Res 1990, 19: 425-34.
54. Becker, R.E., Colliver, J.A., Markwell, S.J., Moriearty, P.L., Unni, L.K., Vicari, S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996, 10: 124-31.
55. Becker, R.E., Colliver, J.A., Markwell, S.J., Moriearty, P.M., Unni, L.K., Vicari, S. Effects of metrifonate on cognitive decline in Alzheimer disease: A double-blind, placebo-controlled, 6-month study. Alzheimer Dis Assoc Disord 1998, 12: 54-7.
56. Morris, J.C., Cyrus, P., Orazem, J., Mas, J., Ruzicka, B., Bieber, F., Gulanski, B. Metrifonate: Potential therapy for Alzheimer's disease. J Neurol Sci 1997, 150(Suppl.): Abst 4-42-05.
57. Metrifonate efficacy in AD demonstrated in clinical trial. Prous Science Daily Essentials September 26, 1997.
58. Pettigrew, L.C., Bieber, R, Lettieri, J. et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998, 38(3): 236-45.